Heterocyclic compounds as kinase inhibitor and uses thereof

US12428395B2 · kind B2 · utility

Assignee

• SPEROGENIX THERAPEUTICS LIMITED · CN

Inventors

• Dhananjay Pendharkar · Noida, IN
• Sreekanth A. Ramachandran · Noida, IN
• Pradeep S. Jadhavar · Noida, IN
• Dayanand PANPATIL · Noida, IN
• Uzma Saeed · New Delhi, IN
• Vivek Kumar · Delhi, IN
• Dipshe Bist · Noida, IN

Key dates

• Filing date: Jul 31, 2020
• Grant date: Sep 30, 2025
• Expiry date: Dec 25, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure relates generally to compounds useful in treatment of conditions associated with Checkpoint kinase (CHK), particularly CHK-1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against CHK-1 enzymes. Methods of treating conditions associated with excessive activity of CHK-1 enzymes with such compounds is disclosed. Uses thereof, pharmaceutical compositions, kits and method of synthesis also disclosed.